International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2025
The comparison of fractional CO2 laser and focused ultrasound for vulvar lichen sclerosus: a retrospective study.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Maoyu, Zhang Xuerui, Xiao Linlin, Liang Jing, Cheng Dan, Zhu Yue, Chang Shufang
Аннотация
OBJECTIVES: To compare the efficacy of fractional carbon dioxide laser (FxCO2) and focused ultrasound (FUS) in treating vulvar lichen sclerosus (VLS).
METHODS: This single-center retrospective study included biopsy-proven VLS patients who did not respond to first-line topical corticosteroids and were treated with FxCO2 or FUS as an alternative between January 2020 and October 2022. The efficacy was evaluated using the Cattaneo score and clinical scoring system (CSS). A subgroup analysis was conducted to compare efficacy based on VLS severity.
RESULTS: At the 3-month follow-up, the total effective rates were similar between FxCO2 (91.18%, 31/34) and FUS (88.57%, 31/35) (p > 0.05). At the 6-month follow-up, the total effective rates for FxCO2 decreased to 85.29% (29/34), while FUS remained at 88.57% (31/35) (p > 0.05). Recurrence rates were 14.7% (5/34) for FxCO2 and 11.4% (4/35) for FUS (p > 0.05) at the 6-month follow-up. Although there was no significant difference in total CSS scores and clinician-administered sign scores between FxCO2 and FUS at both follow-ups (p > 0.05), FxCO2 suggested superior patient-administered symptom improvement at 3-month (median: FxCO2 3 vs. FUS 5, p < 0.05) and 6-month follow-ups (median: FxCO2 3 vs. FUS 5, p < 0.01).
CONCLUSIONS: FxCO2 and FUS show similar efficacy in treating VLS, with FxCO2 suggesting a trend toward greater symptom relief. Further studies are needed to validate these preliminary observations.
METHODS: This single-center retrospective study included biopsy-proven VLS patients who did not respond to first-line topical corticosteroids and were treated with FxCO2 or FUS as an alternative between January 2020 and October 2022. The efficacy was evaluated using the Cattaneo score and clinical scoring system (CSS). A subgroup analysis was conducted to compare efficacy based on VLS severity.
RESULTS: At the 3-month follow-up, the total effective rates were similar between FxCO2 (91.18%, 31/34) and FUS (88.57%, 31/35) (p > 0.05). At the 6-month follow-up, the total effective rates for FxCO2 decreased to 85.29% (29/34), while FUS remained at 88.57% (31/35) (p > 0.05). Recurrence rates were 14.7% (5/34) for FxCO2 and 11.4% (4/35) for FUS (p > 0.05) at the 6-month follow-up. Although there was no significant difference in total CSS scores and clinician-administered sign scores between FxCO2 and FUS at both follow-ups (p > 0.05), FxCO2 suggested superior patient-administered symptom improvement at 3-month (median: FxCO2 3 vs. FUS 5, p < 0.05) and 6-month follow-ups (median: FxCO2 3 vs. FUS 5, p < 0.01).
CONCLUSIONS: FxCO2 and FUS show similar efficacy in treating VLS, with FxCO2 suggesting a trend toward greater symptom relief. Further studies are needed to validate these preliminary observations.